Efficacy of quercetin against chemically induced murine oral squamous cell carcinoma
Author
dc.contributor.author
Droguett, Daniel
Author
dc.contributor.author
Castillo, Christian
Author
dc.contributor.author
Leiva, Elba
Author
dc.contributor.author
Theoduloz, Cristina
Author
dc.contributor.author
Schmeda Hirschmann, Guillermo
Author
dc.contributor.author
Kemmerling Weis, Ulrike
Admission date
dc.date.accessioned
2015-12-15T02:31:35Z
Available date
dc.date.available
2015-12-15T02:31:35Z
Publication date
dc.date.issued
2015
Cita de ítem
dc.identifier.citation
Oncology Letters Volumen: 10 Número: 4 (2015)
en_US
Identifier
dc.identifier.issn
1792-1074
Identifier
dc.identifier.other
DOI: 10.3892/ol.2015.3598
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/135720
General note
dc.description
Artículo de publicación ISI
en_US
Abstract
dc.description.abstract
Oral squamous cell carcinoma (OSCC) is the most common form of head and neck cancer, and oxidative damage is associated with the development of OSCCs. Antioxidants have therefore been proposed for use as chemoprotective agents against different types of cancer. In the present study, the effect of the antioxidant quercetin, administered at doses of 10 and 100 mg/kg/day, was investigated in an experimental murine model of 4-nitroquinoline 1-oxide (4-NQO)-induced carcinogenesis. The survival of the treated animals, the plasmatic levels of reduced glutathione and the type and severity of lesions (according the International Histological Classification of Tumors and Bryne's Multifactorial Grading System for the Invasive Tumor Front) were assessed. Additionally, the organization of the extracellular matrix was analyzed by carbohydrate and collagen histochemistry, and immunohistochemistry was used to assess the expression of the tumor markers proliferating cell nuclear antigen and mutated p53. The results indicate that, despite the promising effect of quercetin in other studies, this drug is ineffective as a chemoprotective agent against 4-NQO-induced OSCC in mice at the assayed doses.